Objectives-To investigate the modifications of uterine and fibroid volume, to study Doppler changes in uterine arteries and fibroid-supplying vessels, and to assess possible symptomatic relief after 3 months of treatment with ulipristal acetate.
F
ibroids occur in 20% to 40% of women of reproductive age, being the most common female benign tumors. 1 Most fibroids are asymptomatic and require no treatment. However, the presence of uterine fibroids may lead to serious clinical symptoms, such as heavy menstrual bleeding, painful menstruation, pelvic pain, pelvic pressure, urinary frequency or urgency, and constipation. 2 The mainstay of treatment of symptomatic uterine fibroids is myomectomy or hysterectomy, 3 but minimally invasive alternative treatments are also used in clinical practice, such as uterine artery embolization. 4 Medical therapies with progestin, progestin-releasing intrauterine devices, and gonadotropin-releasing hormone are also available, but several studies have reported important side effects with oral progestins, such as breakthrough bleeding and increased myoma growth. Artificially induced menopause is a consequence of gonadotropin-releasing hormone treatment, the use of which is in fact approved only for short-term presurgical therapy. 6, 7 Since progesterone plays a fundamental role in stimulation of myoma growth, 8 modulating its pathway with selective progesterone receptor modulators, such as ulipristal acetate represents one new possibility for medical therapy. Thanks to its selective antiproliferative and proapoptotic action, 9 ulipristal acetate has in fact been effective in reducing bleeding and fibroid size. 10 It also has a direct effect on the endometrium and the pituitary gland, inducing amenorrhea without a negative influence on estradiol levels or antiglucocorticoid ativity. 11, 12 Ultrasound (US) evaluation of uterine fibroids after ulipristal acetate treatment confirms a reduction in fibroid volume, 10 but the impact of the therapy on uterine and fibroid vascularization has not yet been well investigated. On the other hand, we know that asoprisnil, another selective progesterone receptor modulator, has been proved to reduce uterine artery blood flow, which in fact contributes to its clinical effect. 13 The aims of this study were to investigate whether, after 3 months of therapy with ulipristal acetate, patients noticed substantial relief of all symptoms reported earlier and whether there were important changes in uterine and fibroid volumes and their vascularization before and after treatment. Finally, we wanted to assess whether the different classes of fibroids, according to the International Federation of Gynecology and Obstetrics (FIGO) classification (Figure 1 ), had different responses to ulipristal acetate. 14 
Materials and Methods
This study was designed as a longitudinal prospective study and was conducted from November 2014 (since the approval of ulipristal acetate in our country) through January 2016 in a single center at the Department of Obstetrics and Gynecology of the University Hospital of Verona. The study involved premenopausal women with levels of follicle stimulating hormone of less than 20 IU/L and estradiol of greater than 20 pg/mL on days 2 to 4 of the menstrual cycle.
Women were eligible for the study if they had at least 1 symptomatic type 2, 3, 4, 5, or 6 uterine fibroid according to the FIGO classification, with a main diameter between 4 and 10 cm as assessed by US. Moreover, they must not have had any previous uterine surgery or suspicious cases of adenomyosis or gynecologic Figure 1 . International Federation of Gynecology and Obstetrics leiomyoma subclassification system. Intracavitary lesions are attached to the endometrium by a narrow stalk and are classified as type 0, whereas types 1 and 2 require a portion of the lesion to be intramural, with type 1 being less than 50% and type 2 at least 50%. Type 3 lesions are totally extracavitary but abut the endometrium. Type 4 lesions are intramural leiomyomas that are entirely within the myometrium, with no extension to the endometrial surface or the serosa. Subserosal (type 5-7) leiomyomas represent the mirror image of the submucosal leiomyomas, with type 5 being at least 50% intramural, type 6 being less than 50% intramural, and type 7 being attached to the serosa by a stalk. malignancy, as determined by the history and clinical and US evaluations. Women were selected after confirmation of no ongoing hormonal treatment and exclusion of current pregnancy. We did not type 0, 1, and 7 fibroids for the study because in these cases, the recommended approach in our clinic is surgery if they are symptomatic. Any medical therapy is indicated before the intervention unless severe anemia is present, for which a supplement is recommended.
All patients included in the study received 5 mg of ulipristal acetate (Esmya; Gedeon Richter, Budapest, Hungary) per day for 3 months consecutively. Treatment was initiated during the first day of menstruation. Patients were informed that ulipristal acetate decreases the volume of uterine myomas and improves heavy menstrual bleeding, 15, 16 but no data are available about its action on other symptoms in women with uterine fibroids; they were also informed about the possible adverse effects of ulipristal acetate. Informed consent was obtained from all individual participants included in the study, and they were requested to report adverse effects arising during the use of the drug. All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the 1964 Declaration of Helsinki and its later amendments.
Patients included in the study were scanned by transvaginal US and evaluated clinically for the symptoms reported at least 1 month before starting the treatment (baseline) and 1 month after finishing the 3-month therapy with ulipristal acetate. Fibroid-related menorrhagia was evaluated by the pictorial blood assessment chart score. This instrument is a self-administered pictorial chart that takes account of the number of sanitary pads and tampons used, presence of blood clots, and episodes of bleeding. The 1-month pictorial blood assessment chart score was calculated from the addition of daily scores for 28 days. A score of higher than 100 during the first 8 days of menstruation was defined menorrhagia. 17 Subjective feelings of pelvic pressure, urinary urgency, and constipation were recorded on a simplified questionnaire containing 2 categories defined as "absent" and "present." The visual analog scale pain score was used to determine the presence or absence of pelvic pain (intermestrual, dysmenorrhea, or both). The cutoff considered affirmative was of 5 of 10 or higher.
All US examinations were performed with a Voluson E8 US system (GE Healthcare, Milwaukee, WI) equipped with a transvaginal transducer (frequency, 6.5 MHz; field of view, 150 8; and number of elements, 192) and were performed with the same power Doppler settings (pulse repetition frequency, 1.0 kHz; gain, 50%; wall filter, 1; frame average, 10; Doppler frequency, Gen; line density, middle; and balance). 11 The following US parameters were evaluated both before and after therapy: uterine volume and vascularization and fibroid location, volume, maximum diameter, and vascularization. Uterine volume (expressed in cubic centimeters) was calculated by measuring the maximum length and the anteroposterior and transverse diameters of the uterine corpus, using the US device software formula for calculation of the uterine volume. Myoma volumes were measured by using the existing 2-dimensional US methods that were already part of the software system of the US device. The FIGO subclassification system was used for defining the myoma location.
14 Uterine and fibroid vascularization was analyzed by studying Doppler waveforms of the right and left uterine arteries and the myoma-supplying vessel, respectively. They were expressed in terms of the pulsatility index (PI) and resistive index (RI).
To reduce interobserver variability associated with power Doppler imaging, measurements were always taken by the same sonographer, with 20 years of experience in obstetric and gynecologic power Doppler evaluations. To reduce intraobserver variation, we used standard rules for uterine and fibroid vessel sampling: the uterine Doppler signal was obtained from the usual site of visualization of each uterine artery, near its origin from the iliac artery, whereas the fibroid signal was obtained from the core artery of the fibroid. For the definition of the myoma-supplying/core vessel, we mean the circumferential vascular pseudocapsule that is typical of fibroid vascularization. The Doppler range gate was applied across each vessel, and the blood flow velocity waveforms were recorded for 3 cardiac cycles; each measurement was repeated 3 times, and the average was calculated and considered the final result ( Figure 2) .
For statistical analyses, data regarding symptoms are presented as frequencies and percentages, whereas US data are expressed as mean 6 standard deviation because of a non-normal distribution. Statistical analyses were conducted with SPSS version 21.0 software (IBM Corporation, Armonk, NY). The Wilcoxon rank sum test and Student t test were used for comparisons between clinical and US features before and after treatment. Correlations were assessed with the Spearman correlation coefficient. The Kruskal-Wallis test was used to detect differences in fibroid responses to treatment in terms of volume and vascularization among the different classes of fibroids. P < .05 was considered statistically significant.
Results
During the period considered, 93 patients with symptomatic fibroids were selected for ulipristal acetate therapy. Ninety-one patients completed the treatment, whereas two interrupted before the end because of side effects. One patient had an urticarial reaction, and the other one had arthritic symptoms; both had immediate improvement after suspension. Fifty-three patients met the criteria to be included in the study, but only 42 underwent the 2 clinical examinations and were therefore considered in the study. Among these patients, ulipristal acetate treatment was well tolerated in general, and only some mild adverse effects were recorded: headache . Twenty-five patients (59.5%) were of caucasian racial origin, whereas 11 (26.3%) were African, 2 (4.7%) Asian, and 4 (9.5%) South American. More than half of patients were nulliparous (25 of 42 [59.5%]), and 19 (45.2%) desired fertility. Considering previous surgery, 10 patients (23.8%) had already had myomectomy for symptomatic fibroids.
All patients self-reported that they followed the instructions regarding the daily therapy regimen correctly. There were no adverse reactions to treatment in the group of patients selected for the study.
Patients' symptoms before and after treatment are shown in Table 1 . After 3 months of ulipristal acetate, the women had a significant improvement of all symptoms reported before the treatment. The median uterine volume before treatment was 269 cm 3 ) and a volume reduction percentage of 14% from the baseline measurements (P < .05). The Spearman correlation test between the initial uterine volume and the percentage of volume reduction after therapy showed a statistically significant positive correlation (P < .05; r 5 0.75).
Regarding uterine power Doppler vascular indices, after 3 months of treatment, the right uterine artery PI increased from 1.70 6 0.58 to 1.86 6 0.49 (P 5 .22), and the left uterine artery PI decreased from 1.90 6 0.64 to 0.83 6 0.12 (P 5 .32). Regarding the uterine artery RI, it increased from 0.78 6 0.14 to 0.81 6 0.13 (P 5 .13) in the right artery and from 0.81 6 0.12 to 0.83 6 0.12 (P 5 .30) in the left artery.
Main fibroid diameters, volumes, and vascular indices before and after 3 months of ulipristal acetate treatment are shown in Table 2 . Considering that some patients had more than 1 fibroid, a total of 73 fibroids were analyzed.
The main reductions of fibroids diameters (19%) and volumes (32.8%) after 3 months of ulipristal acetate therapy were statistically significant independent of their size, type, or location ( Figure 3) . Moreover, in comparison with baseline indices obtained before treatment, the fibroid-supplying vessel PI and RI were significantly different after the treatment, indicating a reduction of fibroid vascularization after ulipristal acetate (Figure 4) .
Dividing the 73 fibroids according to their type, according to the FIGO classification, we obtained 4 different groups because there were no type 3 fibroids in the study population. The different responses to treatment among the groups, regarding modification of the main diameter, volume, and vascularization after and before treatment, are reported in Table 3 .
The overall volume reduction was significantly higher in FIGO type 2 and 5 myomas in comparison with FIGO type 4 and 6 myomas (P 5 .033), and in particular, type 5 fibroids had the highest response to treatment, with a volume decrease rate of 42% after ulipristal acetate. However, there was no significant difference in the diameter decrease or in vascularization reduction, considering fibroid-supplying vessel flow parameters, among the different groups.
Discussion
The effects of ulipristal acetate in controlling excessive bleeding due to induction of amenorrhea by uterine fibroids and its action in reducing fibroid size were previously investigated by 2 large studies 15, 16 and recently confirmed by another study analyzing the same outcomes after long-term intermittent therapy. 10 To the best of our knowledge, this study is the first to also evaluate the other debilitating symptoms in women with uterine fibroids, such as pelvic pain, pelvic pressure, urinary urgency, and constipation. Our results showed a substantial improvement of all of these symptoms after only 3 months of treatment, confirming one of the most important outcomes of ulipristal acetate: improvement of health-related quality of life.
The mechanism of action of ulipristal acetate is well known for its selective antiproliferative and proapoptotic The percentages were calculated from the total number of patients (n 5 42). Data are given as mean 6 SD. activity and its effect on the pituitary gland and the endometrium. 18, 19 However, only 1 study analyzed the impact of the treatment on vascularization of uterine myomas, calculating the 3-dimensional power Doppler vascular indices before and after 3-month therapy with ulipristal acetate. 20 Some authors consider 3-dimensional power Doppler vascular indices to have some limits in gynecology. In fact, artifacts are rather common in cases of tissue inhomogeneity and patient or transducer movements because of the high sensitivity of amplitude-based color Doppler US. [21] [22] [23] Considering the high tissue inhomogeneity in the fibroid that was documented after ulipristal acetate treatment, we decided in our work to study standard Doppler waves with a focus on the PI and RI of uterine arteries and fibroid-supplying vessels to evaluate uterine and fibroid vascularity. In fact, the use of power Doppler US has some advantages in the study of uterine and myoma arteries, since it is sensitive to slow flow and small vessels and does not depend on the angle of insonation. 24 In our study, statistically significant increases in the PI and RI of fibroid-supplying vessels were observed after 3 months of ulipristal acetate, showing a reduction of fibroid vascularization, which we suppose has a role in the shrinkage of leiomyomas. Our results show, in fact, that a 3-month treatment results in an overall 33% reduction of fibroid volume. This finding is consistent with the findings in literature reporting fibroid volume reductions between 21.2% and 36%. 14, 15 With regard to uterine volume, after therapy it had a 14% reduction from its initial dimension, with a mean volume variation of 42 cm 3 , which was significant; moreover, larger uteri had a higher decrease rate than smaller ones.
As to the aspect of vascularity, even if we found that ulipristal acetate treatment resulted in an augmentation of all measured uterine power Doppler indices, this Data are given as mean 6 SD.
Baggio et al-Influence of Ulipristal Acetate on Uterine Fibroids increase did not reach statistical significance, suggesting that, even if ulipristal acetate causes a reduction of uterine vascularization, there might be additional factors influencing regulation of the blood flow in the organ. The significantly increased impedance to blood flow after treatment in leiomyoma-supplying vessels, which was not found in uterine arteries, is probably further proof that ulipristal acetate has a greater effect on fibroid vascularization rather than the entire uterine blood flow, but other studies are needed to confirm this statement.
Once we analyzed fibroid volume and vascularization variations after therapy altogether, we tried to evaluate the same parameters in the different classes of fibroids, according to the FIGO classification, by comparing the results to see whether they had similar responses to treatment. Our results show that the decrease in myoma volume was higher when they were intramural or had a predominant intramural component, and in particular, type 5 fibroids had the highest volume reduction (42%) after ulipristal acetate.
A different response to treatment depending on the location of fibroids was also observed after uterine artery embolization, 25 the reason being different vascularization. However, in our work, there was no significant difference in the diameter decrease or vascularization reduction among the different groups, suggesting that impaired vascularization cannot be the only explanation. There probably are additional factors that may vary in the different classes, which contribute to these alternative responses to treatment. For this reason, in the future, it might be interesting to evaluate, for example, whether there is a different distribution of progesterone receptors in each fibroid type that can explain why the intramural ones have higher response to ulipristal acetate.
This study had some limitations. First of all, the study group was relatively small, and the patients were not blinded to the 3-month therapy with ulipristal acetate, and these factors may have influenced the improvement of the symptoms (placebo effect). We are aware that the findings of this research should be interpreted as preliminary, and other well-designed trials are recommended; in particular, future randomized trials with adequate sample sizes should compare the 3-month ulipristal acetate treatment with 2 repeated 3-month courses of treatment or even more courses, since ulipristal acetate was shown to be well tolerated both in the current study and in previous investigations. 10, 15, 16 A weak point of the study was that the evaluation of pelvic pain was made with the use of a visual analog scale pain score in retrospect, and the definitions of urinary and gastrointestinal symptoms were made with a simplified questionnaire, as we usually do in our clinic. However, the use of standard and validated questionnaires improves the reproducibility and validity of data and must be considered in future studies.
Another limitation of our study regarded vascularization assessment: we only calculated standard power Doppler indices without evaluating 3-dimensional power Doppler indices as well. It could be interesting in the future to compare the results obtained with the two techniques. The same concern should be focused on volume detection, even if the standard technique and 3-dimensional volumetry have already been shown to have similar accuracy in the presence of regular fibroids. 26 In conclusion, our study confirms that ulipristal acetate can be an alternative to hysterectomy for treatment of fibroids. The fibroid vascularization decrease after ulipristal acetate therapy is not only an interesting scientific observation, but it also provides a theoretical rationale for future studies. It might be interesting to investigate the possible relationship between initial fibroid vascularization and the outcome of ulipristal acetate treatment and, in particular, whether a significant correlation exists between the initial Doppler indices and the shrinkage in leiomyoma size. These results can be useful in particular when myomectomy is indicated, to evaluate whether presurgical therapy with ulipristal acetate is recommended. If the aim is just improving symptoms, ulipristal acetate seems to be a good alternative to standard medical therapy because of its proven effectiveness and safety. 10, 27 
